osaühing REVELIKO

Active Registry code 10010560 OÜ Tartu linn Registered 8 Feb 1996

osaühing REVELIKO is a OÜ based in Tartu linn, registry code 10010560, status: active. Main activity: Manufacture of basic pharmaceutical products. According to EMTA, turnover for Q3 2026 was €6 593 with 1 employees.

Turnover

6 593 €

↓ 72.9% vs Q2 2026

State taxes

726 €

↓ 74.3% vs Q2 2026

Labour taxes

103 €

↑ 18.4% vs Q2 2026

Employees

±0 vs Q2 2026

Q3 2026 · data from the Tax and Customs Board (EMTA)

Position in the industry Manufacture of basic pharmaceutical products and pharmaceutical preparations · EMTAK 21

Turnover · Q3 2026 6 593 €

above 10% of companies

industry median 234 187 € · companies in the industry: 12
Labour taxes per employee 103 €

above 2% of companies

industry median 4 573 € · companies in the industry: 12
Revenue · 2025 51 846 €

above 55% of companies

industry median 48 003 € · companies in the industry: 19
Net profit margin · 2025 33.2 %

above 79% of companies

industry median 9.8 % · companies in the industry: 15

Taxes and turnover

Q4 2023 – Q3 2026

Turnover, € Q3 2026: 6 593 € · −72.9% vs Q2 2026 · industry median 234 187 € · above 10% of the industry

Company
Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Labour taxes per employee, € Q3 2026: 103 € · +18.4% vs Q2 2026 · industry median 4 573 € · above 2% of the industry

Company
Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Employees Q3 2026: 1 · +0.0% vs Q2 2026

State taxes, € Q3 2026: 726 € · −74.3% vs Q2 2026

Figures by quarter
Quarter	Turnover, €	State taxes, €	Labour taxes, €	Employees
Q3 2026	6 593	726	103	1
Q2 2026	24 318	2 820	87	1
Q1 2026	20 144	3 796	213	1
Q4 2025	17 557	1 937	104	1
Q3 2025	6 550	286	—	1
Q2 2025	11 098	1 801	204	1
Q1 2025	19 222	2 894	309	1
Q4 2024	14 679	2 309	123	1
Q3 2024	2 866	70	123	1
Q2 2024	6 863	841	123	1
Q1 2024	17 229	2 596	69	1
Q4 2023	12 485	1 457	86	1
Q3 2023	4 456	274	86	1
Q2 2023	5 055	362	86	1
Q1 2023	21 986	3 224	64	1
Q4 2022	17 477	2 575	115	1
Q3 2022	6 189	599	115	1
Q2 2022	6 475	535	89	1
Q1 2022	16 225	2 278	115	1

Labour taxes per employee per month

34 €

Turnover per employee in the quarter

6 593 €

Q3 2026 · calculated from EMTA data

Financials by year

2016 – 2025

Revenue, € 2025: 51 846 € · +41.8% vs 2024 · industry median 48 003 € · above 55% of the industry

Company
Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € 2025: 17 237 € · +543.5% vs 2024 · industry median 676 € · above 70% of the industry

Company
Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit margin, % 2025: 33.2 % · +43.9 pp vs the year before · industry median 9.8 % · above 79% of the industry

Company
Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € 2025: 51 631 € · +64.4% vs 2024

Equity, € 2025: 23 994 € · +255.1% vs 2024

Employees 2025: 1 · +0.0% vs 2024 · industry median 28 · above 5% of the industry

Company
Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year	Revenue, €	Net profit, €	Labour costs, €	Assets, €	Equity, €	Employees
2025	51 846	17 237	5 840	51 631	23 994	1
2024	36 567	-3 887	8 577	31 401	6 757	1
2023	45 711	2 258	7 851	35 788	10 644	1
2022	46 567	-3 851	6 280	33 390	8 386	1
2021	47 098	10 316	6 552	37 172	12 237	1
2020	28 737	-8 664	6 213	26 020	1 921	1
2019	28 809	-5 656	5 751	34 691	10 585	1
2018	—	—	—	—	—	1
2017	—	—	—	—	—	0
2016	—	—	—	—	—	0
2015	—	—	—	—	—	1
2014	—	—	—	—	—	0
2013	—	—	—	—	—	0
2012	—	—	—	—	—	0
2011	—	—	—	—	—	1
2010	—	—	—	—	—	1
2009	—	—	—	—	—	1
2008	—	—	—	—	—	2
2007	—	—	—	—	—	2
2006	—	—	—	—	—	2
2005	—	—	—	—	—	2
2004	—	—	—	—	—	1
2001	—	—	—	—	—	0
2000	—	—	—	—	—	0
1999	—	—	—	—	—	4
1998	—	—	—	—	—	4
1997	—	—	—	—	—	4

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2025

Net profit margin

33.2 %

Net profit / revenue

Return on equity (ROE)

71.8 %

Net profit / equity

Return on assets (ROA)

33.4 %

Net profit / assets

Equity ratio

46.5 %

Equity / assets

Debt ratio

53.5 %

Liabilities / assets

Current ratio

1.87

Current assets / current liabilities

Revenue per employee

51 846 €

Revenue / average full-time employees

Labour cost per employee per month

487 €

Labour costs / employees / 12 months (incl. employer taxes)

Annual reports

PDFs from e-Äriregister

Annual reports
Year	Period	Filed	Report	Documents
2025	1 Jan 2025 – 31 Dec 2025	26 Mar 2026	Company’s own	e-Äriregister
2024	1 Jan 2024 – 31 Dec 2024	10 Feb 2025	Company’s own	e-Äriregister
2023	1 Jan 2023 – 31 Dec 2023	2 Apr 2024	Company’s own	e-Äriregister
2022	1 Jan 2022 – 31 Dec 2022	26 May 2023	Company’s own	e-Äriregister
2021	1 Jan 2021 – 31 Dec 2021	27 Apr 2022	Company’s own	e-Äriregister
2020	1 Jan 2020 – 31 Dec 2020	5 Mar 2021	Company’s own	e-Äriregister
2019	1 Jan 2019 – 31 Dec 2019	26 Jun 2020	Company’s own	e-Äriregister

Board

Jelena Kraus
Board member (manager) · since 8 Feb 1996

Right of representation

Any member of the management board may represent the private limited company in all transactions.

Owners

Aleksandr Anikin
Natural person · 2 556 €

100%

Beneficial owners

Aleksandr Anikin
Direct ownership · since 7 Oct 2018

Founders and other persons

Aleksandr Anikin
Founder · 10 000 € · 8 Feb 1996

shared board members, owners or beneficial owners

Activities (EMTAK)

21101Manufacture of basic pharmaceutical products Main
46321Wholesale of meat and meat products

Rulings 7

All rulings (PDF)

Rulings
Number, date	Title	State	Document
Ä 20000260 / 9 1 Sep 2023	Amendment entry	In force 1 Sep 2023	PDF
Ä 20000260 / 8 17 Jan 2018	Amendment entry	In force 17 Jan 2018	PDF
Ä 20000260 / 7 19 Dec 2017	Amendment entry	In force 19 Dec 2017	PDF
Ä 20000260 / 6 3 Dec 2017	Amendment entry	In force 3 Dec 2017	PDF
Ä 20000260 / 5 29 Jun 2011	Amendment entry	In force 29 Jun 2011	PDF
Ä 260 / 4 8 Dec 2008	Amendment entry	In force 8 Dec 2008	PDF
Ä 260 / 3 3 Dec 2008	Deletion of activities from the registry card	In force 8 Dec 2008	PDF

Sources: e-Äriregister and EMTA. Data updated 1 Nov 2026. Open at the source ↗ · Report an error in the data

osaühing REVELIKO

Position in the industry Manufacture of basic pharmaceutical products and pharmaceutical preparations · EMTAK 21

Taxes and turnover

Financials by year

Financial ratios for 2025

Annual reports

Board

Right of representation

Owners

Beneficial owners

Founders and other persons

Related companies

Activities (EMTAK)

Rulings 7